Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CDKN2A Mutation”

22 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 22 results

Early research (Phase 1)Ended earlyNCT03435250
What this trial is testing

Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss

Who this might be right for
Advanced Solid TumorsLymphoma
Institut de Recherches Internationales Servier 123
Testing effectiveness (Phase 2)Ended earlyNCT02688907
What this trial is testing

Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients With MYC Family Amplification or CDKN2A Mutation Combined With TP53 Mutation

Who this might be right for
Small Cell Lung Cancer
Samsung Medical Center 7
Not applicableLooking for participantsNCT03250078
What this trial is testing

A Pancreatic Cancer Screening Study in Hereditary High Risk Individuals

Who this might be right for
Pancreatic Neoplasms
Nuvance Health 200
Not applicableLooking for participantsNCT05420064
What this trial is testing

An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk and An Intervention to Help Patients and Their Primary Care Providers Stay Up-to-date About Uncertain Genetic Test Results

Who this might be right for
BRCA1 MutationPOLD1 Gene MutationCDKN2A Mutation+19 more
Memorial Sloan Kettering Cancer Center 1,000
Not applicableUnknownNCT03524677
What this trial is testing

Mutation of K-RAS, CDKN2A, SMAD4 and TP53 in Pancreatic Cancer: Role of Liquid Biopsy in Preoperative Diagnosis

Who this might be right for
Pancreatic Cancer
University of Roma La Sapienza 50
Very early researchEnded earlyNCT04074785
What this trial is testing

Abemaciclib w/Bevacizumab in Recurrent GBM Pts w/Loss of CDKN2A/B or Gain or Amplification of CDK4/6

Who this might be right for
GBMGlioblastomaBrain Tumor+1 more
University of Texas Southwestern Medical Center 10
Large-scale testing (Phase 3)Looking for participantsNCT07063745
What this trial is testing

Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

Who this might be right for
Metastatic Non-small Cell Lung Cancer With MTAP Deletion
Bristol-Myers Squibb 590
Very early researchStudy completedNCT02846935
What this trial is testing

P53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies

Who this might be right for
T-cell LymphomaAggressive B-cell LymphomaNon-Hodgkin's Lymphomas+1 more
Yogen Saunthararajah 7
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06509997
What this trial is testing

A Phase II Study of Anti-EGFR Antibody-drug Conjugate (ADC) Combine With CDK4/6 Inhibitors Posterior Line in the Treatment of Recurrent/Metastatic CDKN2A Gene Variant Head and Neck Squamous Cell Carcinoma

Who this might be right for
Head and Neck Squamous Cell Carcinoma
Lei Liu 30
Testing effectiveness (Phase 2)Study completedNCT03356223
What this trial is testing

Evaluation of ABEMACICLIB Monotherapy in Patients With Locally Advanced/Metastatic Head and Neck Cancer After Failure of Platinum and Cetuximab or Anti-EGFR-based Therapy and Harboring an Homozygous Deletion of CDKN2A, and/or an Amplification of CCND1 and/or of CDK6

Who this might be right for
Head and Neck CancerAdvanced CancerMetastatic Cancer
Centre Leon Berard 25
Early research (Phase 1)Study completedNCT02540876
What this trial is testing

Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery

Who this might be right for
Metastatic Malignant NeoplasmSolid NeoplasmUnresectable Malignant Neoplasm
University of Chicago 12
Large-scale testing (Phase 3)Looking for participantsNCT04966481
What this trial is testing

Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor

Who this might be right for
HPV-unrelated Head and Neck Squamous Cell Carcinoma
Washington University School of Medicine 81
Large-scale testing (Phase 3)Looking for participantsNCT02000089
What this trial is testing

The Cancer of the Pancreas Screening-5 CAPS5)Study

Who this might be right for
Pancreas CancerPeutz-Jeghers Syndrome (PJS)Gene Mutation+2 more
Johns Hopkins University 9,000
Early research (Phase 1)Looking for participantsNCT07077434
What this trial is testing

Assess Safety, Tolerability and Drug Levels of BMS-986504 in Participants With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
Bristol-Myers Squibb 32
Testing effectiveness (Phase 2)Study completedNCT02187783
What this trial is testing

LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)

Who this might be right for
Tumors With CDK4/6 Pathway Activation
Novartis Pharmaceuticals 106
Testing effectiveness (Phase 2)WithdrawnNCT06090318
What this trial is testing

Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss

Who this might be right for
Advanced Solid TumorCDKN2ANSCLC+7 more
Rain Oncology Inc
Early research (Phase 1)Looking for participantsNCT04794699
What this trial is testing

Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

Who this might be right for
Solid Tumor
IDEAYA Biosciences 180
Testing effectiveness (Phase 2)Ended earlyNCT03601507
What this trial is testing

Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer

Who this might be right for
CDKN2A-p16 PositiveHPV Positive Oropharyngeal Squamous Cell CarcinomaStage I Oropharyngeal Squamous Cell Carcinoma AJCC V7+3 more
University of Arizona 9
Early research (Phase 1)Looking for participantsNCT05216432
What this trial is testing

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

Who this might be right for
PIK3CA MutationSolid Tumor, AdultHER2-negative Breast Cancer+4 more
Relay Therapeutics, Inc. 930
Testing effectiveness (Phase 2)UnknownNCT02202200
What this trial is testing

Phase I-II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation and Pharmacokinetics of PD-0332991 in Patients Suffering Metastatic Melanoma

Who this might be right for
Melanoma BRAF V600E/K MutatedCDNKN2A Loss Defined
Assistance Publique - Hôpitaux de Paris 40
Load More Results